Xembify Solution
Product Images NDC 13533-810

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Xembify (NDC 13533-810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Grifols Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton3057222

Packaging label for XEMBIFY immune globulin subcutaneous, human-klhw 20%, 10 g/50 mL solution for subcutaneous administration. Manufactured by Grifols USA, LLC, the label states it is Rx only and a single use vial with no preservative. Storage instructions specify refrigeration at 2-8°C or room temperature up to 25°C for a limited time, and warnings about handling and usage are included.*

FDA Label Image

Dosage (Dosage)

A mathematical formula showing the calculation for the initial weekly dose of intravenous immune globulin (IVIG) based on prior IVIG amount and the interval of administration, multiplied by a factor of 1.37. The formula is presented in a clean, black-and-white layout.*

FDA Label Image

Figure 1 (Figure1)

An instructional illustration showing two hands demonstrating how to hold and manipulate a syringe or similar device. One hand grips the upper portion near the plunger, while the other hand holds the lower end, suggesting preparation or administration technique.*

FDA Label Image

Figure 2 (Figure2)

An anatomical illustration showing the front and back views of a human figure with shaded areas indicating recommended subcutaneous injection sites for administration of XEMBIFY (immune globulin subcutaneous, human-klhw) 200 mg/mL solution.*

FDA Label Image

Figure 3 (Figure3)

An instructional illustration showing a hand administering an injection to the abdominal area just below the waistline. The image depicts the injection site for subcutaneous administration, demonstrating proper hand placement and angle for injection.*

FDA Label Image

Figure 4 (Figure4)

An instructional illustration labeled Figure 4, showing a person holding and preparing a device or tubing near the abdominal area for subcutaneous administration, indicating a step in the process of using XEMBIFY immune globulin subcutaneous solution.*

FDA Label Image

Figure 5 (Figure5)

An instructional illustration showing a person receiving a subcutaneous injection in the abdominal area. One hand holds a syringe, while the other pinches the skin to prepare for the injection, demonstrating the administration technique for subcutaneous solutions.*

FDA Label Image

Logo (Logo)

FDA Label Image

Step 10 (Step10)

An instructional illustration showing a person applying a cotton ball or pad to the abdomen, likely demonstrating the care of an injection site for subcutaneous administration.*

FDA Label Image

Step 11 (Step11)

An instructional illustration showing a person preparing or handling a subcutaneous infusion set near the abdomen area. The image focuses on the hands connecting or adjusting part of the tubing or catheter on the skin surface above the waistline.*

FDA Label Image

Step 12 A (Step12)

Illustration showing a person's hands preparing a syringe for subcutaneous injection. The syringe is being filled from a vial or container, demonstrating proper technique likely related to the administration of XEMBIFY, immune globulin subcutaneous, human-klhw solution.*

FDA Label Image

Step 12 B (Step12b)

An instructional illustration showing hands preparing a subcutaneous injection using a syringe connected to tubing inserted into the abdominal area of a person. The image demonstrates the technique for administering a subcutaneous solution, consistent with immune globulin subcutaneous delivery.*

FDA Label Image

Step 3 (Step3)

An instructional illustration showing a person washing hands under running water from a faucet. Two hands are positioned palm-up beneath the water stream, demonstrating a hand hygiene step.*

FDA Label Image

Step 5 (Step5)

An instructional illustration showing two hands preparing a small vial for use. The first image depicts fingers removing a cap from the vial, and the second image shows a hand applying a piece of material, likely an alcohol swab or seal, to the vial's neck.*

FDA Label Image

Step 6 (Step6)

An instructional illustration showing two hands preparing a syringe with a needle. The first hand holds and positions the needle cap, while the second hand demonstrates twisting and removing the cap from the needle. This image likely depicts the preparation process for the subcutaneous administration of XEMBIFY immune globulin solution.*

FDA Label Image

Step 7 (Step7)

Instructional illustrations showing a person preparing a syringe: drawing immune globulin subcutaneous solution from a vial and then holding the syringe, ready for subcutaneous injection, as part of the use process for XEMBIFY 200 mg/mL solution by Grifols USA, LLC.*

FDA Label Image

Step 9 (Step9)

An anatomical illustration showing recommended subcutaneous injection sites on the human body. Shaded areas include the outer upper arms, abdomen (except around the navel), upper outer thighs, and the upper back just below the shoulder blades on both front and back views of a male figure.*

FDA Label Image

Vial (Vial)

Label for XEMBIFY 200 mg/mL solution, immune globulin subcutaneous, human-klhw, for subcutaneous administration. The single-use vial contains 10 g in 50 mL, distributed by Grifols USA, LLC. Storage instructions note temperatures of 2-8°C and up to 25°C for short periods. Additional usage and compatibility information refer to the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.